By Hilary Rosselot
Healx Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Wayne Chadwick, a Principal Pharmacologist at Healx Ltd., presented about the IMPACT-FXS trial during the Industry Updates keynote session at the 18th International Fragile X Conference.
IMPACT-FXS is a Phase 2 trial targeting multiple pathways associated with Fragile X to maximize the number of behaviors treated in individuals with Fragile X syndrome.
Wayne shared more about Healx, their novel AI approach to finding treatments, and their Phase 2 trial. Learn more about Healx and the IMPACT-FXS trial by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Kaerus Bioscience Completes Successful Phase 1 Trial, Demonstrating Promise for KER-0193 BK Channel Modulator for Fragile X Syndrome
Yesterday, Kaerus Bioscience announced that it has successfully completed its Phase 1 trial and demonstrated 'proof of mechanism' with their novel BK channel modulator, KER-0193, being developed for Fragile X Syndrome!
Gene therapies in action: a look at examples of successful treatments
Although there are currently no options for approved or experimental gene therapies for FXS, gene therapies in other diseases and conditions do exist and are helping people today! Read the blog to see some examples of gene therapy in the real world!